nomifensine has been researched along with Adrenal Cancer in 1 studies
Nomifensine: An isoquinoline derivative that prevents dopamine reuptake into synaptosomes. The maleate was formerly used in the treatment of depression. It was withdrawn worldwide in 1986 due to the risk of acute hemolytic anemia with intravascular hemolysis resulting from its use. In some cases, renal failure also developed. (From Martindale, The Extra Pharmacopoeia, 30th ed, p266)
nomifensine : An N-methylated tetrahydroisoquinoline carrying phenyl and amino substituents at positions C-4 and C-8, respectively.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Naoi, M | 1 |
| Takahashi, T | 1 |
| Ichinose, H | 1 |
| Wakabayashi, K | 1 |
| Sugimura, T | 1 |
| Nagatsu, T | 1 |
1 other study available for nomifensine and Adrenal Cancer
| Article | Year |
|---|---|
Uptake of heterocyclic amines, Trp-P-1 and Trp-P-2, into clonal rat pheochromocytoma PC12h cells by dopamine uptake system.
Topics: Adrenal Gland Neoplasms; Animals; Carbolines; Chromatography, High Pressure Liquid; Dopamine; Kineti | 1989 |